In prostate cancer, however, when the Zn2+ concentration is decreased [96,97], ZnR/GPR39 may be re-sensitized, such that extracellular Zn2+ binding to it will activate Ca2+ signaling, leading to proliferation. Here, GPR39 is linked to prostate carcinoma.